Must-See: Elon’s New Invention is Absolutely Insane

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

Kevin Joseph Fitzgerald net worth and biography

Kevin Fitzgerald Biography and Net Worth

EVP of Alnylam Pharmaceuticals

Dr. Kevin Fitzgerald joined Alnylam in 2005 as Associate Director of Research and has served in roles of increasing responsibility and leadership since that time. Kevin was promoted to Chief Scientific Officer of Alnylam in May of 2019; he is also Executive Vice President and Head of Research at Alnylam and has 24 years of drug discovery experience.

His achievements at Alnylam include leadership of the company’s RNAi delivery efforts, resulting in two clinically validated modes of siRNA delivery, and the development of Alnylam’s RNAi therapeutic novel class of medicines. He is an inventor on over 50 patents including the majority of Alnylam’s marketed and pipeline programs, as well as an author of over 50 papers including many in prestigious journals such as Nature, Cell, and New England Journal of Medicine. He has led multiple programs — including Alnylam’s inclisiran program — from discovery through pre-clinical development, regulatory submissions, and early clinical development. Prior to 2005, Kevin was at Bristol-Myers Squibb for 7 years.

Kevin received his Bachelor of Science in genetics from Cornell University and his doctorate in molecular biology from Princeton University/Columbia Medical School. He completed his post-doctoral fellowship in oncology at Harvard Medical School. Kevin also serves on the Scientific Advisory Board of Generation Bio and is an independent board Director for Ovid Therapeutics.

What is Kevin Joseph Fitzgerald's net worth?: The estimated net worth of Kevin Joseph Fitzgerald is at least $3.56 million as of June 25th, 2024. Dr. Fitzgerald owns 14,181 shares of Alnylam Pharmaceuticals stock worth more than $3,559,856 as of July 7th. This net worth evaluation does not reflect any other assets that Dr. Fitzgerald may own. Learn More about Kevin Joseph Fitzgerald's net worth.
How old is Kevin Joseph Fitzgerald?: Dr. Fitzgerald is currently 55 years old. There are 6 older executives and no younger executives at Alnylam Pharmaceuticals. The oldest executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who is 61 years old. Learn More on Kevin Joseph Fitzgerald's age.
How do I contact Kevin Joseph Fitzgerald?: The corporate mailing address for Dr. Fitzgerald and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Kevin Joseph Fitzgerald's contact information.
Has Kevin Joseph Fitzgerald been buying or selling shares of Alnylam Pharmaceuticals?: Kevin Joseph Fitzgerald has not been actively trading shares of Alnylam Pharmaceuticals within the last three months. Most recently, Kevin Joseph Fitzgerald sold 1,198 shares of the business's stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a transaction totalling $276,726.02. Following the completion of the sale, the executive vice president now directly owns 14,181 shares of the company's stock, valued at $3,275,669.19. Learn More on Kevin Joseph Fitzgerald's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 112,501 shares worth more than $22,093,058.52. The most recent insider tranaction occured on June, 25th when CMO Pushkal Garg sold 2,103 shares worth more than $485,771.97. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 6/25/2024.

Kevin Joseph Fitzgerald Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/25/2024	Sell	1,198	$230.99	$276,726.02	14,181

Kevin Joseph Fitzgerald Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $251.03

$246.95

$252.48

50 Day Range

MA: $170.20

$143.95

$251.03

2 Week Range

Now: $251.03

$141.98

$252.87

Volume

685,719 shs

Average Volume

1,715,766 shs

Market Capitalization

$31.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Must-See: Elon’s New Invention is Absolutely Insane

From InvestorPlace | Ad

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

Click here for the full story…

Kevin Fitzgerald Biography and Net Worth

What is Kevin Joseph Fitzgerald's net worth?

How old is Kevin Joseph Fitzgerald?

How do I contact Kevin Joseph Fitzgerald?

Has Kevin Joseph Fitzgerald been buying or selling shares of Alnylam Pharmaceuticals?

Who are Alnylam Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Alnylam Pharmaceuticals?